Tag Archives: sovaldi

April, 2017

November, 2016

  • 22 November

    HCV Research Round-up

    Hepatitis C treatment options continue to be a vibrant field full of exciting research, including the following: Genotype 3 of the hepatitis C virus (HCV) has remained harder-to-treat among the six main genotypes. New research presented at the 2016 AASLD conference now offers promising news for treating genotype 3. According …

February, 2016

  • 9 February

    New Hepatitis C Combo On the Way

    Another once-daily pill is on-track for approval by the U.S. Food and Drug Administration (FDA) for the treatment of hepatitis C, adding to the growing number of treatment options for this life-threatening disease. This time, it’s a combination of Sovaldi® (sofosbuvir) with a new NS5A inhibitor called velpatasvir from Gilead …

January, 2016

  • 5 January

    FDA Grants Priority Review to Gilead’s Latest Hepatitis C Combo

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 4, 2016– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® in …

December, 2015

  • 28 December

    The Promise of Pan-Genotype Cure

    One treatment which works against all strains of the hepatitis C virus (HCV) appears to be getting closer to reality all the time, as I wrote about on October 20, 2015 in One Pill for All Hepatitis C Strains. Gilead Sciences’ Sovaldi (sofosbuvir) combined in one pill with an NS5A inhibitor called …

  • 2 December

    Hepatitis C Deaths Still On Rise

    The headlines are compelling when it comes to new medications for treating infection with the hepatitis C virus (HCV): Harvoni cures up to 98% of patients with genotype 1 HCV. Viekira Pak cures 100% of those with genotype 1b HCV. Sovaldi cures 95% of those with genotype 2 HCV. With …

April, 2015

  • 23 April

    Gilead and Merck Present Positive Data for Next-Generation Hepatitis C Drug Regimens

    At The International Liver Congress, both Gilead Sciences and Merck announced positive results from hepatitis C trials, evaluating their next-generation hepatitis C combo drugs. Gilead revealed preclinical data and results from a mid-stage study supporting the development of its investigational all-oral, three-drug regimen of Sovaldi (sofosbuvir), the investigational NS5A inhibitor …

  • 14 April

    Specialty Drugs Drove Significant Increase in US Drug Spending in 2014

    Driven by innovative, yet expensive new specialty drugs, US spending on prescription drugs jumped 13 percent to $374 billion in 2014, the largest percentage increase since 2001, according to a new report. The significant increase was primarily due to the introduction of expensive breakthrough drugs, manufacturer price hikes and a …

  • 7 April

    Value vs. Cost

    Ever since new (and admittedly high-cost) hepatitis C treatments hit the market, the price of curing hepatitis C has been under the microscope. News outlets repeatedly cite the $1,000 per pill price of Sovaldi or the $84,000 total price tag for the 12-week treatment course. So what are patients getting …

March, 2015